IFN-α treatment inhibits acute friend retrovirus replication primarily through the antiviral effector molecule Apobec3

Journal of Immunology

Volumn 190, Issue 4, 2013, Pages 1583-1590

  Harper, Michael S ^a,b   Barrett, Bradley S ^a   Smith, Diana S ^a   Li, Sam X ^a,b   Gibbert, Kathrin ^c   Dittmer, Ulf ^c   Hasenkrug, Kim J ^d   Santiago, Mario L ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MESSENGER RNA; PROTEIN APOBEC3; PROTEIN IFITM3; PROTEIN ISG15; PROTEIN MX1; PROTEIN OAS1; PROTEIN PKR; PROTEIN SAMHD1; PROTEIN TRIM25; TETHERIN PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIPERIN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FRIEND LEUKEMIA VIRUS; GENE EXPRESSION; IMMUNE RESPONSE; IN VIVO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RETROVIRUS INFECTION; UPREGULATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS RELEASE;

ACUTE DISEASE; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTIDINE DEAMINASE; FRIEND MURINE LEUKEMIA VIRUS; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RETROVIRIDAE INFECTIONS; VIREMIA; VIRUS REPLICATION;

EID: 84873545923     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202920     Document Type: Article

References (67)

1. Muller, F. 2006. Overview of clinical applications of Type I Interferons. In The Interferons: Characterization and Application. A. Meager, ed. Wiley-VCH, Weinheim, p. 277-308.
2. Hatzakis, A., P. Gargalianos, V. Kiosses, M. Lazanas, V. Sypsa, C. Anastassopoulou, V. Vigklis, H. Sambatakou, C. Botsi, D. Paraskevis, and C. Stalgis. 2001. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J. Interferon Cytokine Res. 21: 861-869.
3. Emilie, D., M. Burgard, C. Lascoux-Combe, M. Laughlin, R. Krzysiek, C. Pignon, A. Rudent, J. M. Molina, J. M. Livrozet, F. Souala, et al; Primoferon A Study Group. 2001. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 15: 1435-1437.
4. Asmuth, D. M., R. L. Murphy, S. L. Rosenkranz, J. J. Lertora, S. Kottilil, Y. Cramer, E. S. Chan, R. T. Schooley, C. R. Rinaldo, N. Thielman, et al; AIDS Clinical Trials Group A5192 Team. 2010. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis. 201: 1686-1696.
5. Pillai, S. K., M. Abdel-Mohsen, J. Guatelli, M. Skasko, A. Monto, K. Fujimoto, S. Yukl, W. C. Greene, H. Kovari, A. Rauch, et al; Swiss HIV Cohort Study. 2012. Role of retroviral restriction factors in the interferon-a-mediated suppression of HIV-1 in vivo. Proc. Natl. Acad. Sci. USA 109: 3035-3040.
6. Saito, M., M. Nakagawa, S. Kaseda, T. Matsuzaki, M. Jonosono, N. Eiraku, R. Kubota, N. Takenouchi, M. Nagai, Y. Furukawa, et al. 2004. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 189: 29-40.
7. Yamasaki, K., J. Kira, Y. Koyanagi, Y. Kawano, N.Miyano-Kurosaki, M. Nakamura, E. Baba, J. Suzuki, A. Yamamoto, N. Yamamoto, and T. Kobayashi. 1997. Longterm, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J. Neurol. Sci. 147: 135-144.
8. de Veer, M. J., M. Holko, M. Frevel, E. Walker, S. Der, J. M. Paranjape, R. H. Silverman, and B. R. Williams. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69: 912-920.
9. Schoggins, J. W., S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones, P. Bieniasz, and C. M. Rice. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
10. Hervas-Stubbs, S., J. L. Perez-Gracia, A. Rouzaut, M. F. Sanmamed, A. Le Bon, and I. Melero. 2011. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17: 2619-2627.
11. Malim, M. H., and P. D. Bieniasz. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2: a006940.
12. Duggal, N. K., and M. Emerman. 2012. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 12: 687-695.
13. Yap, M. W., G. B. Mortuza, I. A. Taylor, and J. P. Stoye. 2007. The design of artificial retroviral restriction factors. Virology 365: 302-314.
14. Metz, P., E. Dazert, A. Ruggieri, J. Mazur, L. Kaderali, A. Kaul, U. Zeuge, M. P. Windisch, M. Trippler, V. Lohmann, et al. 2012. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56: 2082-2093 .
15. Liu, S. Y., D. J. Sanchez, R. Aliyari, S. Lu, and G. Cheng. 2012. Systematic identification of type I and type II interferon-induced antiviral factors. Proc. Natl. Acad. Sci. USA 109: 4239-4244.
16. Santiago, M. L., M. Montano, R. Benitez, R. J. Messer, W. Yonemoto, B. Chesebro, K. J. Hasenkrug, and W. C. Greene. 2008. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321: 1343-1346.
17. Takeda, E., S. Tsuji-Kawahara, M. Sakamoto, M. A. Langlois, M. S. Neuberger, C. Rada, and M. Miyazawa. 2008. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J. Virol. 82: 10998-11008.
18. Low, A., C. M. Okeoma, N. Lovsin, M. de las Heras, T. H. Taylor, B. M. Peterlin, S. R. Ross, and H. Fan. 2009. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385: 455-463.
19. Okeoma, C. M., N. Lovsin, B. M. Peterlin, and S. R. Ross. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927-930.
20. Okeoma, C. M., A. Low, W. Bailis, H. Y. Fan, B. M. Peterlin, and S. R. Ross. 2009. Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J. Virol. 83: 3486-3495.
21. Liberatore, R. A., and P. D. Bieniasz. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. USA 108: 18097-18101.
22. Engelhardt, R., A. Mackensen, and C. Galanos. 1991. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51: 2524-2530.
23. Otto, F., P. Schmid, A. Mackensen, U. Wehr, A. Seiz, M. Braun, C. Galanos, R. Mertelsmann, and R. Engelhardt. 1996. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur. J. Cancer 32A: 1712-1718.
24. Krown, S. E., D. Kerr, W. E. Stewart, II, A. K. Field, and H. F. Oettgen. 1985. Phase I trials of poly(I,C) complexes in advanced cancer. J. Biol. Response Mod. 4: 640-649.
25. Freeman, A. I., N. Al-Bussam, J. A. O'Malley, L. Stutzman, S. Bjornsson, and W. A. Carter. 1977. Pharmacologic effects of polyinosinic-polycytidylic acid in man. J. Med. Virol. 1: 79-93.
26. Hasenkrug, K. J., and U. Dittmer. 2007. Immune control and prevention of chronic Friend retrovirus infection. Front. Biosci. 12: 1544-1551.
27. Halemano, K., M. S. Harper, K. Guo, S. X. Li, K. J. Heilman, B. S. Barrett, and M. L. Santiago. 2012. Humoral immunity in the Friend retrovirus infection model. Immunol. Res. DOI: 10.1007/s12026-012-8370-y.
28. Van der Gaag, H. C., and A. A. Axelrad. 1990. Friend virus replication in normal and immunosuppressed C57BL/6 mice. Virology 177: 837-839.
29. Lilly, F., and R. A. Steeves. 1973. B-tropic Friend virus: a host-range pseudotype of spleen focus-forming virus (SFFV). Virology 55: 363-370.
30. + T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J. Virol. 82: 408-418.
31. Santiago, M. L., D. S. Smith, B. S. Barrett, M. Montano, R. L. Benitez, R. Pelanda, K. J. Hasenkrug, and W. C. Greene. 2011. Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cellactivating factor receptor. J. Virol. 85: 189-199.
32. Barrett, B. S., D. S. Smith, S. X. Li, K. Guo, K. J. Hasenkrug, and M. L. Santiago. 2012. A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog. 8: e1002596.
33. Santiago, M. L., R. L. Benitez, M. Montano, K. J. Hasenkrug, and W. C. Greene. 2010. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J. Immunol. 185: 1114-1123.
34. + T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J. Virol. 76: 450-454.
35. Ammann, C. G., R. J. Messer, K. E. Peterson, and K. J. Hasenkrug. 2009. Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS ONE 4: e6105.
36. Gerlach, N., S. Schimmer, S. Weiss, U. Kalinke, and U. Dittmer. 2006. Effects of type I interferons on Friend retrovirus infection. [Published erratum appears in 2007 J. Virol. 81: 6160.] J. Virol. 80: 3438-3444.
37. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
38. Smith, D. S., K. Guo, B. S. Barrett, K. J. Heilman, L. H. Evans, K. J. Hasenkrug, W. C. Greene, and M. L. Santiago. 2011. Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog. 7: e1002284.
39. Gerlach, N., K. Gibbert, C. Alter, S. Nair, G. Zelinskyy, C. M. James, and U. Dittmer. 2009. Anti-retroviral effects of type I IFN subtypes in vivo. Eur. J. Immunol. 39: 136-146.
40. Gibbert, K., J. J. Joedicke, A. Meryk, M. Trilling, S. Francois, J. Duppach, A. Kraft, K. S. Lang, and U. Dittmer. 2012. Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog. 8: e1002868.
41. Kolokithas, A., K. Rosenke, F. Malik, D. Hendrick, L. Swanson, M. L. Santiago, J. L. Portis, K. J. Hasenkrug, and L. H. Evans. 2010. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J. Virol. 84: 10933-10936.
42. Demorest, Z. L., M. Li, and R. S. Harris. 2011. Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J. Biol. Chem. 286: 26568-26575.
43. Chiu, Y. L., H. E. Witkowska, S. C. Hall, M. Santiago, V. B. Soros, C. Esnault, T. Heidmann, and W. C. Greene. 2006. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. USA 103: 15588-15593.
44. Kozak, S. L., M. Marin, K. M. Rose, C. Bystrom, and D. Kabat. 2006. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281: 29105-29119.
45. Li, J., Y. Hakata, E. Takeda, Q. Liu, Y. Iwatani, C. A. Kozak, and M. Miyazawa. 2012. Two genetic determinants acquired late in mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency. PLoS Pathog. 8: e1002478.
46. Mehta, H. V., P. H. Jones, J. P. Weiss, and C. M. Okeoma. 2012. IFN-α and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways. J. Immunol. 189: 4088-4103.
47. Hasenkrug, K. J., and B. Chesebro. 1997. Immunity to retroviral infection: the Friend virus model. Proc. Natl. Acad. Sci. USA 94: 7811-7816.
48. Santiago, M. L., and W. C. Greene. 2008. The role of the Apobec3 family of cytidine deaminases in innate immunity, G-to-A hypermutation and evolution of retroviruses. In Origin and Evolution of Viruses. E. Domingo, C. R. Parrish, and J. J. Holland, eds. Academic Press, London, U.K., p. 183-206.
49. Schmitt, K., K. Guo, M. Algaier, A. Ruiz, F. Cheng, J. Qiu, S. Wissing, M. L. Santiago, and E. B. Stephens. 2011. Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology 419: 24-42.
50. Thielen, B. K., J. P. McNevin, M. J. McElrath, B. V. Hunt, K. C. Klein, and J. R. Lingappa. 2010. Innate immune signaling induces high levels of TCspecific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 285: 27753-27766.
51. Vázquez, N., H. Schmeisser, M. A. Dolan, J. Bekisz, K. C. Zoon, and S. M. Wahl. 2011. Structural variants of IFNa preferentially promote antiviral functions. Blood 118: 2567-2577.
52. Refsland, E. W., J. F. Hultquist, and R. S. Harris. 2012. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8: e1002800.
53. Hultquist, J. F., J. A. Lengyel, E. W. Refsland, R. S. LaRue, L. Lackey, W. L. Brown, and R. S. Harris. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85: 11220-11234.
54. Derse, D., S. A. Hill, G. Princler, P. Lloyd, and G. Heidecker. 2007. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. USA 104: 2915-2920.
55. Miyagi, E., C. R. Brown, S. Opi, M. Khan, R. Goila-Gaur, S. Kao, R. C. Walker, Jr., V. Hirsch, and K. Strebel. 2010. Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84: 11067-11075.
56. Mulder, L. C., M. Ooms, S. Majdak, J. Smedresman, C. Linscheid, A. Harari, A. Kunz, and V. Simon. 2010. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 84: 9613-9617.
57. Stopak, K. S., Y. L. Chiu, J. Kropp, R. M. Grant, and W. C. Greene. 2007. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282: 3539-3546.
58. Refsland, E. W., M. D. Stenglein, K. Shindo, J. S. Albin, W. L. Brown, and R. S. Harris. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38: 4274-4284.
59. Goujon, C., and M. H. Malim. 2010. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J. Virol. 84: 9254-9266.
60. Sarkis, P.T., S.Ying, R.Xu, and X. F.Yu. 2006. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 177: 4530-4540.
61. Chen, K., J. Huang, C. Zhang, S. Huang, G. Nunnari, F. X. Wang, X. Tong, L. Gao, K. Nikisher, and H. Zhang. 2006. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 80: 7645-7657.
62. Koning, F. A., E. N. Newman, E. Y. Kim, K. J. Kunstman, S. M. Wolinsky, and M. H. Malim. 2009. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83: 9474-9485.
63. Peng, G., K. J. Lei, W. Jin, T. Greenwell-Wild, and S. M. Wahl. 2006. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferoninduced anti-HIV-1 activity. J. Exp. Med. 203: 41-46.
64. Rose, K. M., M. Marin, S. L. Kozak, and D. Kabat. 2004. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279: 41744-41749.
65. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
66. Laguette, N., B. Sobhian, N. Casartelli, M. Ringeard, C. Chable-Bessia, E. Ségéral, A. Yatim, S. Emiliani, O. Schwartz, and M. Benkirane. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
67. Hrecka, K., C. Hao, M. Gierszewska, S. K. Swanson, M. Kesik-Brodacka, S. Srivastava, L. Florens, M. P. Washburn, and J. Skowronski. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.